PND2 – A Systematic Review and Network Meta-Analysis of Pharmacological Therapies Used for Patients with Advanced Parkinson's Disease by Ren, S. et al.
This is a repository copy of PND2 – A Systematic Review and Network Meta-Analysis of 
Pharmacological Therapies Used for Patients with Advanced Parkinson's Disease.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/97344/
Version: Accepted Version
Article:
Ren, S., Cooper, K. orcid.org/0000-0002-7702-8103, Cooper, J.A. et al. (2 more authors) 
(2014) PND2 – A Systematic Review and Network Meta-Analysis of Pharmacological 
Therapies Used for Patients with Advanced Parkinson's Disease. Value in Health, 17 (7). 
A390-A390. ISSN 1098-3015 
https://doi.org/10.1016/j.jval.2014.08.856
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
  
A Systematic Review and Network Meta-Analysis of Pharmacological Therapies Used 
for Patients with Advanced Parkinson¶s Disease 
Shijie Ren,1 Katy Cooper,1 James Cooper,2 Helen Smith,2 Soraya Shaikh2 
 
1 School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom 
2
 GlaxoSmithKline, Brentford, Middlesex, United Kingdom 
 
Objectives 
To assess the relative efficacy and safety of modified-release levodopa (IPX066), controlled-
release levodopa and add-on therapy to immediate-release levodopa (including dopamine 
agonists, monoamine oxidase-B inhibitors (MAOBI), and catechol-O-methyl transferase 
inhibitors (COMTI)) using network meta-analysis (NMA). 
 
Methods 
A systematic literature search was conducted in MEDLINE, MEDLINE In-Process, 
EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of 
Controlled Trials, DARE and HTA. A random effects NMA was used to determine the 
relative efficacy and safety of treatments on off-time reduction, three Unified Parkinson¶s 
Disease Rating Scale (UPDRS) scores, patient withdrawals, and six adverse events in 
WinBUGS. An additional analysis was conducted to assess treatment class effects. Node-
splitting approach was used to assess the assumption of consistency when direct and indirect 
evidence was combined. 
 
Results 
Forty-three trials with 9,453 patients were identified. Immediate-release levodopa plus 
pramipexole produced the greatest reduction in off-time relative to immediate-release 
levodopa plus placebo (-1.71 hours a day; 95% CrI: -2.11, -1.35), followed by IPX066 (-1.40; 
95% CrI: -2.19, -0.67). The greatest improvement on UPDRS ADL score was given by add-
on ropinirole (-2.33 points; 95% CrI: -3.53, -1.06); on UPDRS motor and total score was 
given by add-on pramipexole (-5.88 points; 95% CrI: -7.22, -4.63 and -10.09 points; 95% 
CrI: -13.75, -6.56, respectively). Dyskinesia was increased with IPX066 and adjuvant therapy 
classes except for MAOBIs. Patient withdrawals were also increased with IPX066 and 
controlled-release levodopa. 
 
  
Conclusions 
The NMA showed that all treatments except controlled-release levodopa were associated 
with a statistically significant reduction in off-time. Dopamine agonist class as adjunctive to 
levodopa therapy had the greatest reduction. IPX066 was broadly comparable with add-on 
dopamine agonists on off-time reduction, and comparable with add-on MAOBIs and 
COMTIs on UPDRS scores. However, the treatments were associated with an increase in the 
risk of having dopaminergic side effects, particularly dyskinesia. 
